Biocon Biologics Gets USFDA Approval for Cancer Biosimilar - Jobevne
April 10, 2025 11:16
Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various cancers. This approval expands the company's biosimilar oncology portfolio in...